免疫组化标记物鉴别诊断子宫内膜样腺癌与宫颈腺癌的临床意义  

Clinical Significance of Immunohistochemical Markers in the Differential Diagnosis of Endometrioid Adenocarcinoma and Cervical Adenocarcinoma

作　　者：盛仲楠 袁博 沈俏丽 SHENG Zhongnan;YUAN Bo;SHEN Qiaoli(Department of Pathology,Liaocheng Hospital of Traditional Chinese Medicine,Liaocheng,Shandong Province,252000 China)

机构地区：[1]聊城市中医医院病理科,山东聊城252000

出　　处：《系统医学》2022年第22期35-39,共5页Systems Medicine

摘　　要：目的探究免疫组化标记物鉴别诊断子宫内膜样腺癌与宫颈腺癌临床诊断价值。方法选取2019年2月—2021年8月期间聊城市中医医院的子宫内膜样腺癌与宫颈腺癌患者的病理组织样本,共计82份,其中包括子宫内膜样腺癌54份、宫颈腺癌28份,均应用免疫组化法检查组织中波形蛋白(Vimentin)、癌胚抗原(CEA)、雌激素受体(ER)、孕激素受体(PR)、P16情况,分析子宫内膜样腺癌、宫颈腺癌中免疫组化法阳性检出率。结果子宫内膜样腺癌中Vimentin、ER、PR阳性检出率分别为79.63%、74.07%、66.67%,较宫颈腺癌(7.14%、14.29%、42.86%)高,CEA、P16阳性检出率分别为33.33%、27.78%,较宫颈腺癌(89.29%、64.29%)低,差异有统计学意义(χ^(2)=39.126、26.507、4.307、23.146、10.220,P<0.05);Vimentin、ER、PR在Ⅲ期中阳性检出率为100.00%、94.12%、94.12%,均较Ⅰ期(75.00%、50.00%、58.33%)、Ⅱ期(68.00%、72.00%、56.00%)高,差异有统计学意义(P<0.05);CEA在Ⅲ期中阳性检出率为58.82%,较Ⅱ期20.00%高,差异有统计学意义(P<0.05);Vimentin、CEA、ER、PR积分均随子宫内膜样腺癌临床分期的增加而逐渐升高,差异有统计学意义(P<0.05);P16在Ⅲ期中阳性检出率为100.00%,较Ⅰ期(57.14%)、Ⅱ期(41.67%)高,差异有统计学意义(P<0.05);CEA、P16积分均随宫颈腺癌临床分期的增加而逐渐升高,差异有统计学意义(P<0.05)。结论应用免疫组化法检验中,子宫内膜样腺癌Vimentin、ER、PR阳性检出率较高,CEA、P16阳性检出率较低,可用于子宫内膜样腺癌、宫颈腺癌鉴别诊断,且可利用其阳性积分水平变化进行上述两种疾病临床分期评估。Objective To investigate the clinical diagnostic value of immunohistochemical markers for differential diagnosis of endometrioid adenocarcinoma and cervical adenocarcinoma.Methods Pathological tissue samples of patients in Liaocheng Hospital of Traditional Chinese Medicine with endometrioid adenocarcinoma and cervical adenocarcinoma between February 2019 and August 2021 were selected,totaling 82 samples:54 endometrioid adenocarcinomas and 28 cervical adenocarcinomas,all of which were examined for vimentin,carcinoembryonic antigen(CEA),estrogen receptor(ER),progesterone receptor(PR),and P16 in the tissues by immunohistochemistry,and the positive detection rate of immunohistochemistry in endometrioid adenocarcinomas and cervical adenocarcinomas was analyzed.Results The positive detection rates of Vimentin,ER,and PR were 79.63%,74.07%,and 66.67%in endometrioid adenocarcinoma,respectively,which were higher than those in cervical adenocarcinoma 7.14%,14.29%,and 42.86%,and the positive detection rates of CEA and P16 were 33.33%and 27.78%,respectively,which were lower than those in cervical adenocarcinoma 89.29%and 64.29%,the difference was statistically significant(χ^(2)=39.126,26.507,4.307,23.146,10.220,P<0.05).Vimentin,ER,and PR positive detection rates were 100.00%,94.12%,and 94.12%in stageⅢcompared to stageⅠ(75.00%,50.00%,58.33%)were higher than those in stageⅠ(75.00%,50.00%,58.33%)and stageⅡ(68.00%,72.00%,56.00%),and the difference was statistically significant(P<0.05).The positive detection rate of CEA was 58.82%in stageⅢ,which was higher than that in stageⅡ(20.00%),and the difference was statistically significant(P<0.05);the scores of Vimentin,CEA,ER and PR all increased gradually with the increase of clinical stage of endometrioid adenocarcinom,and the difference was statistically significant(P<0.05);the positive detection rate of P16 in stageⅢwas 100.00%,which was higher than stage I(57.14%)and stageⅡ(41.67%),and the difference was statistically significant(P<0.05);CEA and P16 scores increased

关 键 词：子宫内膜样腺癌 宫颈腺癌 免疫组化标记物 

分 类 号：R59[医药卫生—内科学]